Open Actively Recruiting

Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors

About

Brief Summary

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents.

The current subprotocols include the following:

Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens

Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6

Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel

Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens

Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6

Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 1/Phase 2

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

Exclusion Criteria:

Other inclusion/exclusion criteria may apply.

Join this Trial

Share:
Study Stats
Protocol No.
24-5198
Category
Colorectal Cancer
Pancreatic Cancer
Contact
JENNA DAVIS
Location
  • UCLA Burbank
  • UCLA Porter Ranch
  • UCLA San Luis Obispo
  • UCLA Santa Barbara
  • UCLA Santa Monica
  • UCLA Westlake Village
For Providers
NCT No.
NCT06445062
For detailed technical eligibility, visit ClinicalTrials.gov.